FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094133067> ?p ?o ?g. }

• W2094133067 endingPage "381" @default.
• W2094133067 startingPage "371" @default.
• W2094133067 abstract "Given the rapidly increasing number of women above 50 it is of pivotal importance to consider health issues related to gonadal hormone deficiency. The possibility of alleviating such symptoms by hormone replacement therapy (HRT) should be recognized by all physicians, not merely by gynaecologists. But which women should be given what therapy, and for how long? Due to the increased risk of endometrial cancer and bleeding problems when using oestrogen monotherapy, only women who have undergone hysterectomy could use this regimen unless treatment is aimed at amelioration of urogenital symptomatology only. In this case a vaginal administration of low-dose oestrogens is possible as such doses do not induce endometrial proliferation. In all other cases a combination of an oestrogen and a progestogen must be used. There are several options for doing so. During the early phase of the climacteric period when irregular and/or heavy vaginal bleeds are part of the symptomatology a cyclical therapy will often combat these problems. As women pass into the menopause a sequential regimen is often preferred until 1-3 years have elapsed since menopause. With advancing time since menopause women become more and more reluctant to experience monthly bleeds. In such cases a continuous combined regimen may be offered even though it cannot guarantee a bleed-free remedy.Non-oral, particularly transdermal, therapy is an alternative in women with co-existing morbidity such as migraine, diabetes, malfunction of the gastrointestinal tract and liver disease. Oral therapy is preferred particularly in women with elevated plasma levels of LDL-cholesterol, lipoprotein(a) or homocysteine. Oral therapy induces liver protein synthesis. This could be an advantage in cases with low plasma levels of sex hormone-binding globulin (SHBG) as low levels of SHBG may promote androgenic stigmata such as hirsutism and a lowering of the voice. However, in cases with too low an androgen influence the use of a non-oral therapy may counteract symtoms such as low libido.Tibolone could be used for the prevention (and treatment?) of osteoporosis but it will also mitigate the typical climacteric symptoms. Raloxifene is a fairly new type of drug which is classified as a selective oestrogen receptor modulator (SERM). It will reduce vertebral fractures to the same extent as bisphosphonates, albeit the increase in bone density is less. Raloxifene has no effect on climacteric symptoms. Its greatest benefit is a clear reduction of breast cancer in women, which is in contrast to HRT/ERT.There are insufficent data on tibolone and the incidence of breast cancer. Experimental data, however, are intriguing in suggesting less impact on the breast than conventional HRT/ERT." @default.
• W2094133067 created "2016-06-24" @default.
• W2094133067 creator A5066212633 @default.
• W2094133067 date "2002-06-01" @default.
• W2094133067 modified "2023-10-06" @default.
• W2094133067 title "The role of ERT/HRT" @default.
• W2094133067 cites W1964646109 @default.
• W2094133067 cites W2012974823 @default.
• W2094133067 cites W2023211060 @default.
• W2094133067 cites W2030712358 @default.
• W2094133067 cites W2053721374 @default.
• W2094133067 cites W2061801506 @default.
• W2094133067 cites W2068871151 @default.
• W2094133067 cites W2084804973 @default.
• W2094133067 cites W2089752745 @default.
• W2094133067 cites W2140385134 @default.
• W2094133067 cites W2144325254 @default.
• W2094133067 cites W2159394406 @default.
• W2094133067 cites W2167565714 @default.
• W2094133067 cites W2314885285 @default.
• W2094133067 cites W2620960095 @default.
• W2094133067 doi "https://doi.org/10.1053/beog.2002.0286" @default.
• W2094133067 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12099668" @default.
• W2094133067 hasPublicationYear "2002" @default.
• W2094133067 type Work @default.
• W2094133067 sameAs 2094133067 @default.
• W2094133067 citedByCount "21" @default.
• W2094133067 countsByYear W20941330672012 @default.
• W2094133067 countsByYear W20941330672013 @default.
• W2094133067 countsByYear W20941330672017 @default.
• W2094133067 countsByYear W20941330672019 @default.
• W2094133067 countsByYear W20941330672020 @default.
• W2094133067 crossrefType "journal-article" @default.
• W2094133067 hasAuthorship W2094133067A5066212633 @default.
• W2094133067 hasBestOaLocation W20941330671 @default.
• W2094133067 hasConcept C121608353 @default.
• W2094133067 hasConcept C126322002 @default.
• W2094133067 hasConcept C131872663 @default.
• W2094133067 hasConcept C133507102 @default.
• W2094133067 hasConcept C141071460 @default.
• W2094133067 hasConcept C2776259030 @default.
• W2094133067 hasConcept C2777088508 @default.
• W2094133067 hasConcept C2777164284 @default.
• W2094133067 hasConcept C2778562196 @default.
• W2094133067 hasConcept C2779279991 @default.
• W2094133067 hasConcept C2779494336 @default.
• W2094133067 hasConcept C2780159708 @default.
• W2094133067 hasConcept C2780275930 @default.
• W2094133067 hasConcept C2780572241 @default.
• W2094133067 hasConcept C2781413609 @default.
• W2094133067 hasConcept C29456083 @default.
• W2094133067 hasConcept C530470458 @default.
• W2094133067 hasConcept C71924100 @default.
• W2094133067 hasConceptScore W2094133067C121608353 @default.
• W2094133067 hasConceptScore W2094133067C126322002 @default.
• W2094133067 hasConceptScore W2094133067C131872663 @default.
• W2094133067 hasConceptScore W2094133067C133507102 @default.
• W2094133067 hasConceptScore W2094133067C141071460 @default.
• W2094133067 hasConceptScore W2094133067C2776259030 @default.
• W2094133067 hasConceptScore W2094133067C2777088508 @default.
• W2094133067 hasConceptScore W2094133067C2777164284 @default.
• W2094133067 hasConceptScore W2094133067C2778562196 @default.
• W2094133067 hasConceptScore W2094133067C2779279991 @default.
• W2094133067 hasConceptScore W2094133067C2779494336 @default.
• W2094133067 hasConceptScore W2094133067C2780159708 @default.
• W2094133067 hasConceptScore W2094133067C2780275930 @default.
• W2094133067 hasConceptScore W2094133067C2780572241 @default.
• W2094133067 hasConceptScore W2094133067C2781413609 @default.
• W2094133067 hasConceptScore W2094133067C29456083 @default.
• W2094133067 hasConceptScore W2094133067C530470458 @default.
• W2094133067 hasConceptScore W2094133067C71924100 @default.
• W2094133067 hasIssue "3" @default.
• W2094133067 hasLocation W20941330671 @default.
• W2094133067 hasLocation W20941330672 @default.
• W2094133067 hasOpenAccess W2094133067 @default.
• W2094133067 hasPrimaryLocation W20941330671 @default.
• W2094133067 hasRelatedWork W1983608420 @default.
• W2094133067 hasRelatedWork W1997829670 @default.
• W2094133067 hasRelatedWork W2058645302 @default.
• W2094133067 hasRelatedWork W2073698256 @default.
• W2094133067 hasRelatedWork W2269489993 @default.
• W2094133067 hasRelatedWork W2296504085 @default.
• W2094133067 hasRelatedWork W2322008358 @default.
• W2094133067 hasRelatedWork W3024622318 @default.
• W2094133067 hasRelatedWork W4238710827 @default.
• W2094133067 hasRelatedWork W81304678 @default.
• W2094133067 hasVolume "16" @default.
• W2094133067 isParatext "false" @default.
• W2094133067 isRetracted "false" @default.
• W2094133067 magId "2094133067" @default.
• W2094133067 workType "article" @default.